Navigation Links
Myriad publishes clinical utility study for Prolaris
Date:3/3/2014

SALT LAKE CITY, Utah, March 3, 2014 Myriad Genetics, Inc. (Nasdaq: MYGN) today announced that it has published data from the PROCEDE 500 study in the journal Current Medical Research and Opinion, demonstrating that 65 percent of physicians changed their original treatment plans for men with prostate cancer based on results from the Prolaris test. Prolaris is a 46-gene molecular diagnostic test that has been evaluated in 11 clinical studies with more than 5,000 patients.

"Prolaris is an absolute game changer for urologists because it adds meaningful new prognostic information in terms of risk assessment for prostate cancer patients that will improve their care," said E. David Crawford, M.D., head of the Section of Urologic Oncology at the University of Colorado. "In this study, Prolaris led to major changes in therapies with significant reductions or increases in interventional treatments that were based on patients' unique risk profiles."

PROCEDE 500 is a prospective registry study that was designed to evaluate the impact of the Prolaris test on physician treatment recommendations for patients with prostate cancer. In this study of 305 patients, physicians said they would change their treatment plans in 65 percent of cases after receiving the Prolaris report 40 percent of patients had a reduction in therapeutic burden, while 25 percent had an increase in therapeutic burden independent of treatment strategy (i.e., surgery and/or radiation vs. active surveillance and/or watchful waiting). These results are summarized in Table-1 and Table-2 below:

Table 1: Reduction in Therapeutic Burden Among Trial Participants

Number of Patients in the Study Number of Patients Who Saw a Reduction in Therapeutic Burden Percentage Decrease in Therapeutic Burden
305 122 -40%

Table 2: Increase in Therapeutic Burden Among Trial Participants

Number of Patients in the Study Number of Patients Who Saw an Increase in Therapeutic Burden Percentage Increase in Therapeutic Burden
305 76 +25%

The study also evaluated the shift in treatment paradigms from interventional to non-interventional and non-interventional to interventional. Those data appear in the Table-3 and Table-4 below:

Table 3: Planned Interventional Therapy (e.g., Surgery and/or Radiation)

Number of Patients Planned for Interventional Treatment Before Prolaris Test Score Number of Patients Planned for Interventional Treatment After Prolaris Test Score Percentage Decrease in Interventional Therapy
164 103 -37%

Table 4: Planned Non-Interventional Therapy (e.g., Active Surveillance and/or Watchful Waiting)

Number of Patients Planned for Non-Interventional Treatment Before Prolaris Test Score Number of Patients Planned for Non-Interventional Treatment After Prolaris Test Score1 Percentage Increase in Interventional Therapy
141 108 +23%

Importantly, in this study there was an overall 50 percent reduction in surgical interventions and a 30 percent reduction in radiation treatment. Additionally, 96 percent of the 24 patients with initial "undecided" treatment regimens selected non-interventional options after receiving the Prolaris score. These results demonstrate that the Prolaris test is associated with high clinical utility among urologists.

"In multiple clinical studies, Prolaris was shown to provide personalized risk of cancer-specific death, metastases or biochemical failure beyond what is achievable with the Gleason score, clinical stage and PSA data," said Michael Brawer, M.D. vice president of Medical Affairs at Myriad Genetic Laboratories. "PROCEDE 500 demonstrates that the Prolaris score significantly enhances treatment plans for men with localized prostate cancer."

Myriad Submits Updated Clinical Dossier for Medicare Reimbursement Myriad also announced that it has submitted the PROCEDE 500 data as part of the Prolaris clinical dossier to the Centers for Medicare & Medicaid Services (CMS) for Medicare reimbursement. As previously disclosed based on the robust data set from 11 studies with more than 5,000 patients and six publications in peer-reviewed medical journals the company expects a CMS coverage determination on Prolaris by the end of June 2014.

"More than 30,000 men will die from prostate cancer this year, so there is an urgent need to improve clinical care for patients," said Brawer. "Prolaris adds real value to the healthcare system by reducing unnecessary surgeries or exposure to radiation for men at low risk, while increasing medical interventions for men with aggressive prostate cancer, which we believe will save and improve more lives and potentially save the healthcare system more money."


'/>"/>

Contact: Ronald Rogers
rrogers@myriad.com
801-584-3065
Myriad Genetics, Inc.
Source:Eurekalert

Related medicine news :

1. AMP celebrates SCOTUS decision on AMP v. Myriad Case
2. The Laser Outlet Highlights Encouraging Study, Showing Myriad Uses of Medical Lasers
3. SomaLogic publishes proteomic biomarker analysis of lung cancer tissue samples
4. Moffitt researcher publishes book on nutritional management of cancer treatment effects
5. Ear, Nose & Throat Journal publishes research on breakthrough treatment for tonsil stones
6. Natural Sciences Repository Publishes Chromatography and Acidic Compounds Resources
7. ASTRO publishes Safety is No Accident: A Framework for Quality Radiation Oncology and Care
8. Annals of Internal Medicine publishes new CDC recommendations on hepatitis C screening
9. Maturitas publishes clinical guide on low-dose vaginal estrogens for vaginal atrophy
10. Using an HRA to Comply with San Francisco's HCSO Requirements - Zane Benefits Publishes Information
11. Zane Benefits Publishes Information About Over-the-Counter (OTC) Medicines, Drugs and HRAs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: